Our results suggested that Plk1 is also a marker of relapse/resistance in HNSCC and could represent a relevant therapeutic target for these cancers at the diagnosis as previously suggested 21, 22 but also at relapse on reference treatments by chemo/radiotherapy. This evidence concerns the gene PLK1 and cancer.